Fiche publication
Date publication
novembre 2016
Journal
Human immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr FALCOZ Pierre-Emmanuel
,
Pr SCHINI-KERTH Valérie
,
Pr OLLAND Anne
Tous les auteurs :
Olland A, Reeb J, Leclerq A, Renaud-Picard B, Falcoz PE, Kessler R, Schini-Kerth V, Kessler L, Toti F, Massard G
Lien Pubmed
Résumé
Lung transplantation is the only life-saving treatment for end stage respiratory disease. The immediate outcome is still hampered by primary graft dysfunction. The latter is a form of acute lung injury occurring within the 30min following the unclamping of the pulmonary artery that prompts ischemia reperfusion injury. Severe forms may need prolonged mechanical ventilation and extra-corporeal membrane oxygenation. Overall, primary graft dysfunction accounts for at least one third of the deaths during the first post-operative month. Despite increasing experience and knowledge on the underlying cellular events, there is still a lack of an early marker of ischemia reperfusion graft injuries. Microparticles are plasma membrane vesicles that are released from damaged or stressed cells in biological fluids and remodeling tissues, among which the lung parenchyma during acute or chronic injury. We recently evidenced alveolar microparticles as surrogate markers of strong ischemia injury in ex-vivo reperfusion experimental models. We propose herein new insights on how microparticles may be helpful to evaluate the extent of lung ischemia reperfusion injuries and predict the occurrence of primary graft dysfunction.
Mots clés
Animals, Biomarkers, metabolism, Cell-Derived Microparticles, metabolism, Graft Rejection, diagnosis, Humans, Lung, metabolism, Lung Transplantation, Models, Animal, Prognosis, Reperfusion Injury, diagnosis, Spirometry, Treatment Outcome
Référence
Hum. Immunol.. 2016 Nov;77(11):1101-1107
